Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

Acta Oncologica

Volumn 50, Issue 5, 2011, Pages 630-635

  Hofer, Silvia ^a   Elandt, Katarzyna ^c   Greil, Richard ^d   Hottinger, Andreas F ^e   Huber, Urs ^f   Lemke, Dieter ^g   Marosi, Christine ^c   Ochsenbein, Adrian ^h   Pichler, Josef ⁱ   Roelcke, Ulrich ^j   Weder, Patrik ⁱ   Zander, Thilo ⁱ   Wick, Wolfgang ^g   Weller, Michael ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Private Medical University Salzburg   (Austria)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f KLINIK IM PARK   (Switzerland)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ Landesnervenklinik ^*  (Switzerland)

^j CANTONAL HOSPITAL AARAU   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DOXORUBICIN; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER RADIOTHERAPY; CANCER SURGERY; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEINURIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR RECURRENCE; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REGISTRIES; STANDARD OF CARE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956135686     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.572913     Document Type: Article

References (16)

1. Central Brain Tumour Registry of the United States. CBTRUS Statistical Report: Primary brain and central nervous system tumours diagnosed in the United States in 2004 - 2006. 2010.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
4. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10:162-70.
5. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003; 62:297-303. (Pubitemid 36591966)
6. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al. Safety and effi cacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009; 75:156-63.
7. Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-73.
8. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-9. (Pubitemid 350086473)
9. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9. (Pubitemid 46424067)
10. Wick W, Weller M, van den BM, Stupp R. Bevacizumab and recurrent malignant gliomas: A European perspective. J Clin Oncol 2010;28:e188 - 9.
11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-40.
12. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumour progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5.
13. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906-20.
14. Roth P, Wick W, Weller M. Steroids in neurooncology: Actions, indications, side-effects. Curr Opin Neurol 2010.
15. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28: 1168-74.
16. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.J Clin Oncol 2007; 25:3357-61. (Pubitemid 47325623)